http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories
-
Isoray Announces First Quarter Fiscal 2023 Financial Results and Provides Update to Pending Merger
-
Isoray To Announce First Quarter Fiscal 2023 Financial Results on November 10, 2022
-
Isoray Medical, Inc. and Viewpoint Molecular Targeting, Inc. Announce Investor Webcast on October 19, 2022 at 4:15 p.m. EDT
-
Isoray Announces Transformational Merger and Fourth Quarter and Full-Year Fiscal Year End 2022 Financial Results
-
Isoray To Announce Fourth Quarter and Fiscal Year End 2022 Financial Results on September 28, 2022
-
Isoray’s Cesium-131 Featured in Presentations at American Brachytherapy Society’s Annual Conference
-
Isoray To Host Lunch Symposium At American Brachytherapy Society’s Annual Conference
-
Isoray Announces Record Third Quarter Fiscal 2022 Financial Results
-
Isoray To Announce Third Quarter Fiscal 2022 Financial Results on May 10, 2022
-
Isoray to Participate in the Oppenheimer 32nd Annual Healthcare Conference
-
IsoRay (ISR) Reports Study Showing Excellent Outcomes for Intermediate Risk Prostate Cancer Patients Treated with Isoray’s Cesium-131
-
Study Finds Excellent Outcomes for Intermediate Risk Prostate Cancer Patients Treated with Isoray’s Cesium-131
-
Isoray Announces Second Quarter Fiscal 2022 Financial Results
-
Isoray To Announce Second Quarter Fiscal 2022 Financial Results on February 8, 2022
-
Isoray Announces First Quarter Fiscal 2022 Financial Results
-
Isoray To Announce First Quarter Fiscal 2022 Financial Results on November 10, 2021
-
IsoRay (ISR) Announces American Brachytherapy Society LDR Prostate Brachytherapy Treatment Consensus Paper Recognizes Cesium-131
-
American Brachytherapy Society LDR Prostate Brachytherapy Treatment Consensus Paper Recognizes Isoray’s Cesium-131
-
Isoray Reschedules Fourth Quarter and Fiscal Year End 2021 Financial Results Conference Call to September 22, 2021 Due to Conference Provider Technical Issues
-
Isoray Announces Fourth Quarter and Full-Year Fiscal Year End 2021 Financial Results
-
Isoray To Announce Fourth Quarter and Fiscal Year End 2021 Financial Results on September 21, 2021
-
Isoray Announces Third Quarter Fiscal 2021 Financial Results
-
Isoray To Announce Third Quarter Fiscal 2021 Financial Results on May 13, 2021
-
Isoray Announces the Appointment of Donna Fort as Vice President Sales and Marketing
-
University Hospitals Cleveland Medical Center Pilot Study Shows Promise for High-Risk Recurrent Head and Neck Cancer Treatment with Cesium-131 and Surgical Resection
-
Isoray to Present at the Oppenheimer 31st Annual Healthcare Conference
-
Isoray Announces the Appointment of Lisa Lauer As Vice President Business Development
-
Isoray Announces Second Quarter Fiscal 2021 Financial Results
-
Isoray To Announce Second Quarter Fiscal 2021 Financial Results on February 9, 2021
-
IsoRay (ISR) Prices $45 Million Public Offering of Common Stock at $1.25/sh
-
Isoray Announces Pricing of $45 Million Public Offering
-
IsoRay (ISR) to Offer Common Stock
-
Isoray Announces Proposed Underwritten Public Offering
-
Isoray to Present at the H.C. Wainwright BioConnect 2021 Conference
-
C4 Imaging Announces Sirius Positive Signal MRI Marker Given FDA 510(k) Clearance for Use with Isoray's (ISR) Cesium-131 Brachytherapy Seeds to Treat Prostate Cancer
-
C4 Imaging Announces Sirius Positive Signal MRI Marker Given FDA 510(k) Clearance for Use with Isoray’s Cesium-131 Brachytherapy Seeds to Treat Prostate Cancer
-
Isoray’s Cesium-131 Spotlighted in Multiple Presentations at ASTRO
-
Isoray Announces First Quarter Fiscal 2021 Financial Results
-
Isoray To Announce First Quarter Fiscal 2021 Financial Results on November 10, 2020
-
IsoRay (ISR) Prices 9.135M Share & Warrants Offering at $0.52/Sh
-
Isoray, Inc. Announces Pricing of $9.5 Million Public Offering
-
IsoRay (ISR) Announces Proposed Underwritten Public Offering of Common Stock, Warrants
-
Isoray, Inc. Announces Proposed Underwritten Public Offering
-
Isoray Announces Fourth Quarter and Full-Year Fiscal Year End 2020 Financial Results
-
Isoray to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
-
Isoray To Announce Fourth Quarter and Fiscal Year End 2020 Financial Results on September 17, 2020
-
GT Medical Technologies Announces Data Demonstrating Positive Local Control and Safety Outcomes with GammaTile Therapy for Large Brain Metastases
-
Isoray and University of Cincinnati Physicians Company Sign Research Agreement to Study Treatment of Head and Neck Cancers
-
Second Ten Year Data Report Demonstrates Efficacy of Isoray’s Cesium-131 Internal Radiation Therapy in the Treatment of Prostate Cancer
-
Isoray Announces Record Third Quarter Fiscal 2020 Financial Results

